On September 12, 2024, the U.S. Food and Drug Administration (FDA) announced its approval of Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) for subcutaneous injection, commonly known as a shot. This approval included all the same uses of Tecentriq (atezolizumab) that [...]
By Brittney Nichols, MPH-RN, Senior Specialist, Science and Research, Andrew Ciupek, PhD, Associate Director, Clinical Research, Courtney Granville, PhD, MSPH, Chief Scientific Officer Receiving a lung cancer diagnosis can be a scary, life-changing experience. While modern medicine has led [...]
By Renee Botello MSc, Navigator, Treatment and Trials, GO2 for Lung Cancer and Roy Herbst, MD, PhD Each year, the American Society of Clinical Oncology (ASCO) holds an annual meeting that shares novel breakthroughs and transformative research in oncology. [...]
By Shanada Monestime, PharmD, BCOP, Director, Community Engaged Research, and Fatima Mohamed, BSc, Manager, Community Research Implementation In the evolving landscape of healthcare research, community-engaged research (CER) is transforming the way studies are conducted and applied. Imagine a research [...]
By Renee Botello MSc, Navigator, Treatment and Trials, GO2 for Lung Cancer “[In the past] walking through ASCO, you were hard pressed to find anybody working in lung cancer, and now you’re hard pressed on finding somebody who is [...]
Researchers, oncologists, pulmonologists, thoracic surgeons, and patients convene at the World Conference on Lung Cancer (WCLC) each year to discuss developments impacting the lung cancer community. This year the International Association for the Study of Lung Cancer (IASLC)’s [...]
GO2 for Lung Cancer is excited to announce the publication of our brand-new handbook, Navigating Small Cell Lung Cancer: 360° of HOPE. Download or order your free hard copy today. When you or someone you love is diagnosed with [...]
On August 19, 2024, the U.S. Food and Drug Administration (FDA) announced their approval of an exciting new treatment combination: Rybrevant (amivantimab-vmjw) combined with Lazcluze (lazertinib). This treatment combination is meant for people who are newly diagnosed with non-small cell [...]
On August 15, 2024, the U.S. Food and Drug Administration (FDA) granted approval for the immunotherapy drug Imfinzi (durvalumab) to be used in combination with chemotherapy (neoadjuvant, treatment given before surgery) as well as on its own after surgery (adjuvant). [...]
The American Society of Clinical Oncology (ASCO) hosts an annual meeting every spring. At this meeting, oncologists, physicians, researchers, industry members, advocacy organizations (like GO2,) patients, and caregivers come together to share and learn about the latest and most [...]